Aarti Pharma Labs

[Prdnt_investor]

Good Summary

Ranvir's Portfolio

Aarti Pharmalabs - Q2 FY 25 results and concall highlights - Revenues - 458 vs 439 cr, up 4 pc EBITDA - 94 vs 88 cr, up 6 pc (margins @ 20.5 vs 20 pc) PAT - 54 vs 52 cr, up 5 pc Manufacturing footprint - Dombivali - Unit 1 - for APIs, Intermediates, CDMO Vapi - Unit -2 - for APIs, Intermediates, CDMO Tarapur - Unit -3 - for Xanthine and derivatives Unit -4 - for APIs, CDMO Unit -5 - for Xanthine and derivatives Unit -6 - for Xanthine Intermediates Atali - New unit under construct…